Kane Biotech Statistics
Total Valuation
Kane Biotech has a market cap or net worth of 7.74 million. The enterprise value is 9.04 million.
| Market Cap | 7.74M |
| Enterprise Value | 9.04M |
Important Dates
The next estimated earnings date is Thursday, May 22, 2025.
| Earnings Date | May 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 166.77M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.72% |
| Shares Change (QoQ) | -15.33% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 100.70M |
Valuation Ratios
The trailing PE ratio is 1.83.
| PE Ratio | 1.83 |
| Forward PE | n/a |
| PS Ratio | 5.35 |
| PB Ratio | -6.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.13 |
| EV / Sales | 6.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.14 |
Financial Position
The company has a current ratio of 0.43
| Current Ratio | 0.43 |
| Quick Ratio | 0.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -7.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -59.98% |
| Return on Invested Capital (ROIC) | -351.30% |
| Return on Capital Employed (ROCE) | -4,658.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.21% in the last 52 weeks. The beta is 0.43, so Kane Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -54.21% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 14.43 |
| Average Volume (20 Days) | 21,646 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kane Biotech had revenue of 1.45 million and earned 4.24 million in profits.
| Revenue | 1.45M |
| Gross Profit | 606,110 |
| Operating Income | -2.73M |
| Pretax Income | -3.11M |
| Net Income | 4.24M |
| EBITDA | -2.57M |
| EBIT | -2.73M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 249,377 in cash and 1.51 million in debt, giving a net cash position of -1.26 million.
| Cash & Cash Equivalents | 249,377 |
| Total Debt | 1.51M |
| Net Cash | -1.26M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.13M |
| Book Value Per Share | n/a |
| Working Capital | -959,875 |
Cash Flow
In the last 12 months, operating cash flow was -2.86 million and capital expenditures -17,195, giving a free cash flow of -2.87 million.
| Operating Cash Flow | -2.86M |
| Capital Expenditures | -17,195 |
| Free Cash Flow | -2.87M |
| FCF Per Share | n/a |
Margins
Gross margin is 41.91%, with operating and profit margins of -188.53% and 293.05%.
| Gross Margin | 41.91% |
| Operating Margin | -188.53% |
| Pretax Margin | -214.88% |
| Profit Margin | 293.05% |
| EBITDA Margin | -178.03% |
| EBIT Margin | -188.53% |
| FCF Margin | n/a |
Dividends & Yields
Kane Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.72% |
| Shareholder Yield | -4.72% |
| Earnings Yield | 54.73% |
| FCF Yield | -37.13% |
Stock Splits
The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Mar 13, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |